Sun Pharmaceutical Industries Limited has received regulatory approval to manufacture and market a generic version of semaglutide injection in South Africa.
The approval allows Sun Pharma to manufacture and commercialise generic semaglutide for the treatment of adults with inadequately controlled Type 2 diabetes mellitus as an adjunct to diet and exercise.
According to the company, South Africa becomes the second market after India where it has secured regulatory clearance for generic semaglutide.
Sun Pharma said it intends to launch the product in South Africa in the coming days.
The medicine will be offered as a pre-filled, multi-dose injectable pen in 2 mg/1.5 mL and 4 mg/3 mL strengths, enabling flexible once-weekly dosing for patients.
The company highlighted that South Africa continues to witness a rising prevalence of Type 2 diabetes, driven by rapid urbanisation and changing lifestyles.
Sun Pharma believes improved access to affordable treatment options can help address the growing healthcare burden associated with the disease.
The company said the approval demonstrates its capability to develop and manufacture complex generic medicines that meet stringent regulatory standards across multiple markets.
Sun Pharma added that it remains focused on improving access to evidence-based therapies for patients and healthcare professionals worldwide.
Read More: Affordable Rental Housing Scheme Under PMAY-U 2.0: Eligibility, Rent, Benefits and Accommodation Types!
As of 15 July 2026, at 11:09 AM, Sun Pharma share price was trading at ₹1,955.90 per share, reflecting a surge of 0.68% from the previous trading session.
The South African approval strengthens Sun Pharma's international generics portfolio and expands the reach of its generic semaglutide offering. The planned launch is expected to support access to diabetes treatment while reinforcing the company's presence in global specialty and generic pharmaceutical markets.
Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 15, 2026, 1:51 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
